- Nintedanib
- Pirfenidone
- Other Drug Types
Idiopathic Pulmonary Fibrosis Market was valued at USD 4,287.3 million in 2023 and is expected to grow at a 7.2% CAGR from 2024 to 2030. Idiopathic Pulmonary Fibrosis is a chronic lung disease characterized by thickening and stiffening of lung tissue, leading to decreased lung function. The increase in global population, especially the growing geriatric population as well as the surge in the population of smokers worldwide contributes to the growth of the idiopathic pulmonary fibrosis market. According to BioNews, Inc., as of October 2021, current smokers are at higher risk of idiopathic pulmonary fibrosis as compared to former smokers. The increasing prevalence of idiopathic pulmonary fibrosis presents a significant opportunity for market growth. As the aging population grows, so does the incidence of idiopathic pulmonary fibrosis. Improved diagnostic testing and awareness campaigns have led to earlier detection and diagnosis.
Moreover, ongoing research and development activities focused on fibrotic diseases, including idiopathic pulmonary fibrosis, offer promising opportunities. Biopharmaceutical companies are investing in novel therapies and treatment options for idiopathic pulmonary fibrosis. However, novel therapeutic interventions for idiopathic pulmonary fibrosis are necessary as approved therapies are limited to slowing the progression of the disease. Secondly, the development of novel therapies for idiopathic pulmonary fibrosis has been hampered by inadequate animal models, the lack of interventions that promote epithelial repair, and the lack of understanding of the contribution of the aging process to damage and fibrosis. Pirfenidone is an orally administered drug with antifibrotic, anti-inflammatory, and antioxidant effects. This drug is used to slow the disease progression in patients with idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis). Unlike other therapies, pirfenidone is an oral medication that provides patients convenience and ease of administration. It has a favorable safety profile and is generally well-tolerated, making it a suitable option for long-term treatment. Innovations in antifibrotic agents, tyrosine kinase inhibitors, and other modes of action provide hope for improved patient outcomes. These advancements contribute to the expansion of the idiopathic pulmonary fibrosis market.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The increasing prevalence of idiopathic pulmonary fibrosis presents a significant opportunity for market growth. As the aging population grows, so does the incidence of idiopathic pulmonary fibrosis. Improved diagnostic testing and awareness campaigns have led to earlier detection and diagnosis. The COVID-19 pandemic has also heightened awareness of respiratory health, including idiopathic pulmonary fibrosis. Patients recovering from COVID-19 face a higher risk of developing lung fibrosis, leading to increased demand for idiopathic pulmonary fibrosis drugs and therapies. Moreover, healthcare professionals and the general population now recognize the importance of timely intervention and management, driving demand for idiopathic pulmonary fibrosis drugs and therapies.
Idiopathic Pulmonary Fibrosis Market was valued at USD 4,287.3 million in 2023 and is expected to grow at a 7.2% CAGR from 2024 to 2030.
Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., MediciNova Inc., and Jubliant Pharma Limited are some of the major players operating in the idiopathic pulmonary fibrosis market.
Asia Pacific is estimated to grow at the highest CAGR over the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the idiopathic pulmonary fibrosis market.
The growing geriatric population and increase in number of smokers are likely to drive the market.
1.Executive Summary |
2.Global Idiopathic Pulmonary Fibrosis Market Introduction |
2.1.Global Idiopathic Pulmonary Fibrosis Market - Taxonomy |
2.2.Global Idiopathic Pulmonary Fibrosis Market - Definitions |
2.2.1.Molecule |
2.2.2.Mode of Action |
2.2.3.End User |
2.2.4.Region |
3.Global Idiopathic Pulmonary Fibrosis Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Idiopathic Pulmonary Fibrosis Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Idiopathic Pulmonary Fibrosis Market By Molecule, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Nintedanib |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Pirfenidone |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Other Drug Types |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6.Global Idiopathic Pulmonary Fibrosis Market By Mode of Action, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Antifibrotic Agents |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Tyrosine Kinase Inhibitors |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Other Modes of Action |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Idiopathic Pulmonary Fibrosis Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospitals and Clinics |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Other End Users |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Idiopathic Pulmonary Fibrosis Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Idiopathic Pulmonary Fibrosis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Molecule Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Nintedanib |
9.1.2.Pirfenidone |
9.1.3.Other Drug Types |
9.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Antifibrotic Agents |
9.2.2.Tyrosine Kinase Inhibitors |
9.2.3.Other Modes of Action |
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals and Clinics |
9.3.2.Pharmacies |
9.3.3.Other End Users |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Idiopathic Pulmonary Fibrosis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Molecule Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Nintedanib |
10.1.2.Pirfenidone |
10.1.3.Other Drug Types |
10.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Antifibrotic Agents |
10.2.2.Tyrosine Kinase Inhibitors |
10.2.3.Other Modes of Action |
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals and Clinics |
10.3.2.Pharmacies |
10.3.3.Other End Users |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Idiopathic Pulmonary Fibrosis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Molecule Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Nintedanib |
11.1.2.Pirfenidone |
11.1.3.Other Drug Types |
11.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Antifibrotic Agents |
11.2.2.Tyrosine Kinase Inhibitors |
11.2.3.Other Modes of Action |
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals and Clinics |
11.3.2.Pharmacies |
11.3.3.Other End Users |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Idiopathic Pulmonary Fibrosis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Molecule Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Nintedanib |
12.1.2.Pirfenidone |
12.1.3.Other Drug Types |
12.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Antifibrotic Agents |
12.2.2.Tyrosine Kinase Inhibitors |
12.2.3.Other Modes of Action |
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals and Clinics |
12.3.2.Pharmacies |
12.3.3.Other End Users |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Idiopathic Pulmonary Fibrosis Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Molecule Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Nintedanib |
13.1.2.Pirfenidone |
13.1.3.Other Drug Types |
13.2. Mode of Action Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Antifibrotic Agents |
13.2.2.Tyrosine Kinase Inhibitors |
13.2.3.Other Modes of Action |
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals and Clinics |
13.3.2.Pharmacies |
13.3.3.Other End Users |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.United Therapeutics Corporation |
14.2.2.Boehringer Ingelheim International GmbH |
14.2.3.Bristol-Myers Squibb Company |
14.2.4.Cipla Inc. |
14.2.5.Hoffmann-La Roche Ltd |
14.2.6.FibroGen Inc. |
14.2.7.MediciNova Inc. |
14.2.8.Jubliant Pharma Limited (Jubliant Cadista Limited) |
14.2.9.Merck & Co. Inc. |
14.2.10.Horizon Therapeutics Inc. |
14.2.11.Avalyn Pharma Inc. |
14.2.12.CS Pharmaceuticals |
15. Research Methodology |
16. Appendix and Abbreviations |